Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXIN vs CEDILANID-D
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation and atrial flutter for rate control (off-label: paroxysmal supraventricular tachycardia)
Heart failure,Atrial fibrillation,Atrial flutter
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Primarily hepatic via CYP3A4 and renal excretion of unchanged drug; undergoes biliary excretion and enterohepatic recirculation.
Hepatic (minor); primarily renally excreted unchanged.
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
25-30% bound primarily to albumin.
25-30% bound to plasma albumin.
Vd approximately 6-7 L/kg; indicates extensive tissue binding, particularly to cardiac muscle.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
Oral: 60-80%; Intravenous: 100%.
Oral: 70-80%; IV: 100%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or use 0.125 mg every 48 hours; GFR <10 m L/min: reduce dose by 75% or use 0.0625 mg daily; monitor digoxin levels.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
No specific Child-Pugh based dose adjustment; use caution in severe hepatic impairment due to potential toxicity; monitor levels.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Loading dose: 10-15 mcg/kg orally divided every 8 hours over 24 hours; maintenance: 5-10 mcg/kg/day orally in 2 divided doses; maximum 0.25 mg/day.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Start with 0.0625-0.125 mg orally daily; adjust based on renal function and drug levels; due to decreased lean body mass and renal clearance.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
None; however, toxicity is common and potentially fatal. Not a formal black box warning due to age of drug.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
Toxicity risk: hypokalemia, hypomagnesemia, hypercalcemia increase sensitivity,Renal impairment requires dose adjustment,Digoxin immune Fab for life-threatening overdose,Pregnancy category C,Monitor serum levels and ECG
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Hypersensitivity,Ventricular fibrillation,AV block (unless pacemaker present),Wolff-Parkinson-White syndrome with atrial fibrillation,Hypertrophic obstructive cardiomyopathy,Hypokalemia or hypercalcemia (relative)
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
High-fiber foods (bran) may decrease absorption; take digoxin 2 hours before or after high-fiber meals. Potassium-rich foods (bananas, oranges, spinach) can affect toxicity risk; maintain consistent intake. Avoid excessive licorice (glycyrrhizin can cause hypokalemia). Grapefruit juice may increase digoxin absorption; avoid large amounts.
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Risk of fetal toxicity (bradycardia, arrhythmias) if maternal serum levels are supratherapeutic; therapeutic maternal levels are generally safe. Chronic use may be associated with reduced birth weight.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
Digoxin is excreted into breast milk in low concentrations. M/P ratio approximately 0.6–0.9. At typical maternal doses (0.125–0.5 mg/day), the estimated infant dose is less than 10% of the weight-adjusted neonatal maintenance dose, usually considered compatible with breastfeeding. Monitor infant for signs of digoxin toxicity (bradycardia, poor feeding, vomiting).
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
Pregnancy increases glomerular filtration rate (GFR) and volume of distribution, which may lower serum digoxin concentrations; dose adjustments are often needed. Monitor serum levels and adjust dose to maintain therapeutic range (0.5–2.0 ng/m L). Consider increasing dose by 30-50% in later pregnancy if levels are low; postpartum dose may need reduction to prepregnancy levels.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
Check serum digoxin level 6-8 hours after last dose; therapeutic range 0.5-2.0 ng/m L. Hypokalemia, hypomagnesemia, hypercalcemia increase toxicity risk. Use with caution in renal impairment (reduce dose). Monitor for bradycardia and arrhythmias. Avoid in patients with AV block (except pacemaker) or hypertrophic cardiomyopathy. Loading dose: 10-15 mcg/kg lean body weight. Maintenance: 0.125-0.25 mg daily. Consider drug interactions with amiodarone, verapamil, quinidine, and macrolides.
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Take digoxin exactly as prescribed, usually once daily. Do not miss doses or double up.,Monitor pulse before each dose; hold and contact prescriber if heart rate <60 bpm.,Report symptoms of toxicity: nausea, vomiting, diarrhea, blurred vision, yellow-green halos, confusion, or irregular heartbeat.,Avoid over-the-counter antacids, laxatives, or kaolin-pectin; they reduce absorption. Take digoxin 2 hours apart from such products.,Maintain consistent intake of potassium-rich foods (bananas, oranges) unless otherwise instructed. Avoid excessive salt substitutes.,Keep all appointments for blood tests (digoxin levels, potassium, kidney function).,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXIN vs CEDILANID-D, answered by our medical review team.
LANOXIN is a Cardiac Glycoside that works by Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.. CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXIN and CEDILANID-D depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXIN is: 0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.. The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXIN and CEDILANID-D in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXIN is classified as Category C. Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant dose. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.